| 14.53 -0.11 (-0.75%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 19.25  |
1-year : | 22.65 |
| Resists | First : | 16.48 |
Second : | 19.39 |
| Pivot price | 16.02 |
|||
| Supports | First : | 11.77 |
Second : | 9.8 |
| MAs | MA(5) : | 15.07 |
MA(20) : | 15.53 |
| MA(100) : | 13.5 |
MA(250) : | 10.91 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 15.6 |
D(3) : | 25.8 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 19.39 | Low : | 5.78 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TENX ] has closed above bottom band by 17.5%. Bollinger Bands are 28.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.85 - 14.97 | 14.97 - 15.05 |
| Low: | 13.97 - 14.1 | 14.1 - 14.19 |
| Close: | 14.36 - 14.56 | 14.56 - 14.7 |
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Sat, 25 Jul 2026
What's Driving Tenax Therapeutics' Recent Surge - Kavout | AI
Fri, 24 Jul 2026
Tenax Therapeutics, Inc. Revenue Breakdown – NASDAQ:TENX - TradingView
Fri, 24 Jul 2026
Tenax Therapeutics Inc (TENX) Institutional Confidence - TradingKey
Thu, 23 Jul 2026
Millennium Management LLC Reduces Stake in Tenax Therapeutics Inc - GuruFocus
Wed, 22 Jul 2026
Evercore ISI initiates Tenax Therapeutics stock coverage with outperform rating - Investing.com
Tue, 21 Jul 2026
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 76.4 (%) |
| Shares Short | 1,790 (K) |
| Shares Short P.Month | 792 (K) |
| EPS | -1.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -51.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -10.31 |
| PEG Ratio | 1.4 |
| Price to Book value | 6.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|